Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC

Author:

Hong Lingzhi,Negrao Marcelo V.,Dibaj Seyedeh S.,Chen Runzhe,Reuben Alexandre,Bohac Jadi M.,Liu Xiaoke,Skoulidis Ferdinandos,Gay Carl M.,Cascone Tina,Mitchell Kyle G.,Tran Hai T.,Le Xiuning,Byers Lauren A.,Sepesi Boris,Altan Mehmet,Elamin Yasir Y.,Fossella Frank V.,Kurie Jonathan M.,Lu Charles,Mott Frank E.,Tsao Anne S.,Rinsurongkawong Waree,Lewis Jeff,Gibbons Don L.,Glisson Bonnie S.,Blumenschein George R.,Roarty Emily B.,Futreal P. Andrew,Wistuba Ignacio I.,Roth Jack A.,Swisher Stephen G.,Papadimitrakopoulou Vassiliki A.,Heymach John V.,Lee J. Jack,Simon George R.,Zhang Jianjun

Funder

Amgen

University of Texas MD Anderson Cancer Center

MedImmune

AstraZeneca

Bristol-Myers Squibb

Lilly

AbbVie

PharmaMar

Genentech

Takeda

Sanofi

Bayer

Novartis

AstraZenaca

Merck

Roche

Regeneron

GlaxoSmithKline

Kite Pharma

Pfizer

EMD Serono

Johnson & Johnson

Celgene

ACEA Biosciences

National Institutes of Health

National Cancer Institute

American Cancer Society

MD Anderson

Cancer Prevention and Research Institute of Texas

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3